TScan Therapeutics (NASDAQ:TCRX) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research note published on Monday, Benzinga reports. They currently have a $11.00 price target on the stock.

A number of other equities research analysts have also weighed in on the company. Wedbush reaffirmed an outperform rating and set a $10.00 target price on shares of TScan Therapeutics in a research report on Monday, May 13th. HC Wainwright reaffirmed a buy rating and set a $15.00 target price on shares of TScan Therapeutics in a research report on Tuesday, June 4th. Finally, BTIG Research started coverage on TScan Therapeutics in a research report on Thursday, May 16th. They issued a buy rating and a $12.00 price target for the company. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of Buy and a consensus target price of $12.00.

TScan Therapeutics Trading Down 1.7 %

TCRX traded down $0.10 during trading hours on Monday, reaching $5.90. 8,335 shares of the company’s stock traded hands, compared to its average volume of 255,165. The company has a quick ratio of 5.23, a current ratio of 5.23 and a debt-to-equity ratio of 0.19. The firm has a 50-day moving average price of $6.93 and a 200 day moving average price of $7.16. The firm has a market capitalization of $311.87 million, a PE ratio of -4.69 and a beta of 0.83. TScan Therapeutics has a 52-week low of $1.97 and a 52-week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Monday, May 13th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.07). The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $3.75 million. TScan Therapeutics had a negative net margin of 653.50% and a negative return on equity of 61.13%. As a group, sell-side analysts predict that TScan Therapeutics will post -1.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in TCRX. Dimensional Fund Advisors LP bought a new position in shares of TScan Therapeutics in the 2nd quarter worth $70,000. Pale Fire Capital SE increased its position in TScan Therapeutics by 30.2% during the 4th quarter. Pale Fire Capital SE now owns 21,573 shares of the company’s stock valued at $126,000 after buying an additional 4,998 shares in the last quarter. Cornercap Investment Counsel Inc. acquired a new position in TScan Therapeutics during the 2nd quarter valued at about $134,000. Cannon Global Investment Management LLC acquired a new position in TScan Therapeutics during the 1st quarter valued at about $139,000. Finally, Rhumbline Advisers acquired a new position in TScan Therapeutics during the 2nd quarter valued at about $274,000. 82.83% of the stock is owned by institutional investors.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.